Ishita Drugs & Industries Q3FY26 Results: Revenue Falls 24% to ₹313.62 Lakhs
Ishita Drugs & Industries Limited reported Q3FY26 revenue of ₹313.62 lakhs, declining 24.08% year-over-year, with net profit falling 34.63% to ₹15.55 lakhs. However, nine-month performance showed resilience with revenue growing 11.23% to ₹1,160.48 lakhs and net profit increasing 3.60% to ₹60.11 lakhs. The company invested ₹165 lakhs in manufacturing facility upgradation for Revised Schedule M compliance, completing significant civil work and capital expenditure during the quarter.
*this image is generated using AI for illustrative purposes only.
Ishita Drugs & Industries Limited announced its unaudited financial results for the third quarter of fiscal year 2026, ending December 31, 2025. The pharmaceutical company's performance showed a mixed trend with quarterly revenue declining year-over-year while nine-month figures demonstrated growth.
Quarterly Financial Performance
The company's Q3FY26 results reflected challenging market conditions with revenue from operations declining significantly compared to the previous year.
| Financial Metric: | Q3FY26 | Q3FY25 | Change (%) |
|---|---|---|---|
| Revenue from Operations: | ₹313.62 lakhs | ₹413.18 lakhs | -24.08% |
| Total Income: | ₹323.28 lakhs | ₹419.88 lakhs | -23.01% |
| Net Profit: | ₹15.55 lakhs | ₹23.79 lakhs | -34.63% |
| Basic EPS: | ₹0.52 | ₹0.80 | -35.00% |
Other income for the quarter increased to ₹9.66 lakhs from ₹6.70 lakhs in Q3FY25. Total expenses decreased to ₹304.06 lakhs compared to ₹388.09 lakhs in the corresponding quarter of the previous year.
Nine-Month Performance Analysis
Despite the quarterly decline, the company's nine-month performance showed positive momentum across key financial parameters.
| Parameter: | 9M FY26 | 9M FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations: | ₹1,160.48 lakhs | ₹1,043.37 lakhs | +11.23% |
| Total Income: | ₹1,185.94 lakhs | ₹1,060.95 lakhs | +11.78% |
| Net Profit: | ₹60.11 lakhs | ₹58.02 lakhs | +3.60% |
| Basic EPS: | ₹2.01 | ₹1.94 | +3.61% |
The nine-month results indicate the company's resilience and ability to maintain growth trajectory despite quarterly fluctuations in the pharmaceutical sector.
Manufacturing Facility Upgradation Progress
The company made substantial progress on its manufacturing facility upgradation project for compliance with Revised Schedule M requirements during Q3FY26.
| Investment Category: | Amount |
|---|---|
| Civil Work Expenditure: | ₹65 lakhs |
| Capital Expenditure: | ₹100 lakhs |
| Total Investment: | ₹165 lakhs |
Key developments included the near completion of a new block designed to accommodate expanded warehouse area, along with repairs and renovations of various existing building sections. The company also placed orders for utilities and equipment necessary for Revised Schedule M compliance.
Operational Highlights
The company operates within a single business segment focused on pharmaceutical business, as per Indian Accounting Standard (IndAS) on Operating Segments. The paid-up equity share capital remained stable at ₹299.03 lakhs with a face value of ₹10.00 per share.
Employee benefit expenses for Q3FY26 stood at ₹36.08 lakhs compared to ₹35.73 lakhs in Q3FY25. Finance costs decreased to ₹1.54 lakhs from ₹1.83 lakhs year-over-year, indicating improved financial management.
Board Meeting and Regulatory Compliance
The Board of Directors approved the unaudited financial results at their meeting held on February 7, 2026. The results were reviewed by the Audit Committee and subjected to limited review by the company's statutory auditors, Jaymin Shah & Associates, Chartered Accountants. The financial results comply with Indian Accounting Standards and SEBI listing regulations.
Historical Stock Returns for Ishita Drugs & Indus
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.08% | +6.73% | -8.77% | -6.44% | -14.71% | +136.95% |
16
